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AbstrAct:
When one considers the organism Salmonella enterica serotype Typhimurium (S. 
Typhimurium), one usually thinks of the Gram-negative enteric pathogen that 
causes the severe food borne illness, gastroentertitis. In this context, the idea of 
Salmonella being exploited as a cancer therapeutic seems pretty remote. However, 
there has been an escalating interest in the development of tumor-therapeutic 
bacteria for use in the treatment of a variety of cancers. This strategy takes 
advantage of the remarkable ability of certain bacteria to preferentially replicate 
and accumulate within tumors. In the case of S. Typhimurium, this organism infects 
and selectively grows within implanted tumors, achieving tumor/normal tissue 
ratios of approximately 1,000:1. Salmonella also has some attractive properties well 
suited for the design of a chemotherapeutic agent. In particular, this pathogen can 
easily be manipulated to carry foreign genes, and since this species is a facultative 
anaerobe,  it is able to survival in both oxygenated and hypoxic conditions, 
implying this organism could colonize both small metastatic lesions as well as 
larger tumors. These observations are the impetus to a burgeoning field focused 
on the development of Salmonella as a clinically useful anti-cancer agent. We will 
discuss three cutting edge technologies employing Salmonella to target tumors. 
IntroductIon
Bacteria have been investigated as therapeutic 
agents for tumors for over 150 years, when it was first 
observed by William B. Coley that a fraction of cancer 
patients who developed post-operative bacterial infections 
went into remission and were cured of their tumors [1]. 
Although the mechanisms underlying this observation 
were unclear, it was known even then that bacteria 
exhibit immunostimulatory properties. Moreover, it has 
been known for nearly 50 years that anaerobic bacteria 
can selectively grow in tumors, underscoring the fact 
that such microbes have the potential to overcome 
many of the delivery barriers that hinder conventional 
chemotherapeutics [2]. In particular, the conditions that 
permit anaerobic bacterial growth, such as impaired 
circulation, and extensive necrosis, are found in many 
tumors signifying that bacterial therapeutic conduits may 
serve as a unique portal to a wide variety of malignancies. 
Recent advances in molecular biology, as well as the 
complete sequencing of many bacterial genomes, have 
fueled a resurgence of interest in bacteria as drug delivery 
vehicles and tumoricidal agents. Here we will highlight 
recent advances exploiting the use of the food-borne 
pathogen Salmonella enterica serotype Typhimurium (S. 
Typhimurium), as an intriguing chemotherapeutic agent.
the benefIts of bActerIAl cAncer 
therApy
Current chemotherapeutics (and radiation) used 
in the treatment of cancer patients have considerable 
limitations, including toxicity, poor tumor targeting, 
and inadequate tissue penetration, which together often Oncotarget 2010; 1:  721 - 728 722 www.impactjournals.com/oncotarget
result in incomplete destruction of the tumors. Selected 
bacteria, however, can be manipulated to overcome many 
of the limitations that frequently hamper current cancer 
regiments by directly targeting cancer cells, killing these 
cells through innate bacterial toxicity, competition for 
nutrients or delivery of anti-cancer agents. Salmonella, 
Clostridium, Escherichia, Bifodobacterium, Caulobacter 
and Listeria species have all been tested for their potential 
use in cancer therapy with varying degrees of success 
[3,4,5,6,7,8]. 
Bacterial toxins that are highly immunogenic have 
also been manipulated by linking them to tumor antigens 
in an attempt to elicit an immune response to tumors and 
sensitize the immune system to tumor presence [9,10]. 
Furthermore, bacteria such as S. Typhimurium have an 
innate advantage as a chemotherapeutic considering they 
are attracted to cancer cells by compounds released by 
necrotic or quiescent cells within the tumor, thereby they 
can be used to either infect cells or deliver compounds 
directly to the tumor site [8,11,12,13]. Interestingly, 
bacteria have also evolved to overcome several of the 
limitations of conventional therapy given that these 
organisms can penetrate deep into tumors and are 
unaffected by the immune evasion strategies deployed 
by tumors that can make cancer treatment so challenging 
(Figure 1).
sAlmonellA typhImurIum As A 
treAtment optIon
Clostridium and Salmonella species have historically 
been used most successfully as anti-cancer microbes 
[1,2,14,15,16]. These organisms have been used directly 
as therapeutics, as well as delivery vehicles for anti-
Figure 1: Schematic representing the advantages offered by Salmonella (SL) as a cancer therapeutic agent. Green box represents 
how the conventional chemotherapeutic agent (blue pentagon) is unable to penetrate deep into the fast growing tumor. Blue box represents 
the engineered-Salmonella therapy. Salmonella offers several advantages like (i) tumor-specificity, (ii)self-replicating potential, (iii) ability to be 
genetically engineered with either (a) gene silencing (red box), or (b) tumor sensitizing  (brown box) or (c) bacterial toxin/effectors producing 
methodologies  (purple box), leading to tumor regression by caspase-3 mediated and other mechanisms, (iv) ability to migrate to distal regions 
of the tumor and (v) most importantly to induce gap-junction in tumors leading to immune activation against the tumor.
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cancer therapeutics. However, recent advances in tumor 
targeting with attenuated S. Typhimurium have selected 
this pathogen as the bacterium of choice for cancer therapy 
development resulting in it being employed in human 
trials [17,18,19]. Moreover, unlike the strictly anaerobic 
Clostridium which must be delivered in spore form, S. 
Typhimurium is motile, easily genetically manipulated, 
and grows as a facultative anaerobe in the presence 
or absence of oxygen. These and other advantages 
(summarized in Table 1) allow S. Typhimurium to not only 
target tumors, but also deliver therapeutic compounds or 
immune modulators to the tumor site. 
The anoxic environment often found in tumors 
makes the tumor site an attractive niche for S. 
Typhimurium growth. Through the use of their flagella, 
Salmonella migrate towards the tumor, attracted by the 
high concentrations of nutrients available within the 
tumor microenvironment [20,21,22]. The metabolism of 
S. Typhimurium has been exploited to attenuate the strains 
used in cancer therapy, manipulating the bacteria so that 
they grow only at tumor sites. Metabolic genes have 
been removed from S. Typhimurium, such as purI in the 
table 1: Advantages of salmonella as an anti-tumor agent
Feature Underlying Reason References
Systemic administration VNP20009 can be delivered intravenously or by
direct injection into a tumor
[17,35,44]
Tumor specificity Salmonella can accumulate at levels 1,000 fold
higher in tumors as opposed to normal tissues
reducing the risk of toxic side effects of proteins
or compounds delivered systemically.
[21,45,46]
Replication competent Unlike other therapeutic agents Salmonella
replicates at the tumor site so that a low‐dose
replicates to an effective dose within the target
tumor
[24,44,45,47]
Broad tumor specificity Salmonella targets a broad range of solid tumors,
including melanoma, lung, colon, breast, renal,
hepatic, and prostate tumors
[22,48,49,50,51,5
2,53,54,55]
Delivery capacity Salmonella is metabolically active and can
continuously produce a protein of interest during
infection of the tumor
[10,37,56,57,58]
Anti‐tumor Immune 
activation
Salmonella infection induces the upregulation of
Cx43 protein. This results in the formation of
functional Gap‐junctions in tumors leading to
transfer of tumor antigenic peptides to the DCs
and eventually recruiting CD8 T cells
[32,34,59]
Antibiotic sensitivity Salmonella can be easily removed following
treatment with antibiotics
Native cytotoxicity Ability of the bacteria to produce virulence factors
that leads to cytotoxicity and attract immune cells
to the tumors helps in further tumor regression
[50,60]
Post delivery detection  Engineered Salmonella expresses fluorescent
proteins that offers the ability to be externally
detected
[47,61,62,63]Oncotarget 2010; 1:  721 - 728 724 www.impactjournals.com/oncotarget
mutant strain VNP20009, rendering the mutant bacterium 
auxotrophic for certain compounds that are found in very 
high concentrations at tumor sites, in this case purines 
[23]. Such genetic engineering, forces migration of S. 
Typhimurium towards tumors in order to survive and 
results in the bacteria accumulating at the tumor site at 
over a 1,000 times higher levels than in normal tissue [24]. 
Migration towards the tumor site is based on the 
ability of S.  Typhimurium to sense nutrients using a 
number of receptors that are located at the bacterial poles 
on the outer membrane of the bacteria. Two notable 
receptors have been characterized; the TAR receptor, 
which detects aspartate secreted by cancerous tissues 
and the TRG receptor, which aids in migration towards 
ribose found in necrotic tissues [21]. Further manipulation 
of this ability to chemotax towards tumors may lead to 
the development of bacteria that are directed toward 
specific regions within tumors. Towards this end, it was 
discovered that the aspartate receptor controls migration 
towards tumors, the serine receptor initiates penetration, 
and the ribose/galactose receptor directs Salmonella into 
necrotic regions [21]. Therefore knocking out a particular 
receptor may help direct Salmonella to particular region 
within the tumor. Other alterations, such as truncation of 
lipid A [23], reduces the immunogenicity of the bacteria, 
which in turn, reduces the risk of an adverse inflammatory 
reaction and possible toxic shock. 
exploItIng sAlmonellA 
typhImurIum tumor tArgetIng
S. Typhimurium, once at the tumor site, is thought 
to help destroy tumors through competition for nutrients 
and innate toxicity as a result of damage due to growth 
of the bacteria and production of toxins. Presently, S. 
Typhimurium is being used to target and destroy tumors in 
three specific ways: i) delivery of anti cancer compounds, 
ii) sensitizing the immune system to the presence of 
tumors, and iii) using bacterial toxins to directly activate 
caspase-3, a key enzyme of the apoptotic pathway (Figure 
1).
using salmonella to deliver anti cancer 
compounds:
Bacteria have been recently described as “tiny 
programmable robot factories” for use in cancer therapy 
[25]. Indeed, there are numerous compounds that can 
be delivered via bacteria to a tumor site including 
cytotoxic agents, green fluorescent protein for targeting 
and visualization of tumors, DNA for gene therapy, and 
small interfering RNAs (siRNA) to target expression of 
key proteins within tumors [11,22,26,27,28,29,30,31]. 
While these techniques have had varying levels of success 
in animal models, it is inferred that these practices when 
used in combination with the native toxicity of Salmonella 
may offer a fascinating alternative to traditional gene 
therapy approach. 
It is envisaged that specific anti-cancer molecules 
delivered by S. Typhimurium can be used to target the 
outer regions of the tumor with the bacteria invading 
deep within the tumor, penetrating regions of the tumor 
architecture that conventional therapies cannot reach 
[12,32]. One of the key challenges with conventional 
chemotherapy is delivery of potentially toxic agents 
to the appropriate areas of the tumor while preventing 
damage to healthy tissue. Temporal control over bacterial 
delivery of therapeutic agents is a key consideration as 
delivery of these compounds during transit to the tumor 
site will distribute products systemically and increase 
toxicity in healthy tissues. Inducible gene promoters offer 
a solution that is presently employed. Detection of small 
molecules by the bacteria, or irradiation at the point where 
expression is required, have both been used successfully 
in vivo along with the use of pro-drugs introduced at the 
tumor site for conversion into an anticancer agent by 
the bacteria upon contact [13,32,33]. recA, the radiation 
inducible promoter, was linked to tumor necrosis factor 
(TNF)-related apoptosis inducing ligand (TRAIL) to 
control its expression by Salmonella during infection 
of tumors [32]. S. Typhimurium at the tumor site was 
then induced to express TRAIL by doses of radiation, 
which simultaneously treated the tumor. S. Typhimurium 
promoters  specifically  induced  by  hypoxia  have  been 
identified and may be of use in the future, with bacterial 
expression of a therapeutic compound activated once the 
bacteria reach the tumor [33]. 
A second approach for controlling therapeutic 
delivery is the construction of bacteria that produce 
enzymes converting harmless pro-drugs into active 
agents inside the tumor. Toward this goal Salmonella has 
been engineered to express cytosine deaminase (CDase) 
that cleaves the pro-drug 5-fluorocytosine to the active 
chemotherapeutic 5-fluorouricil [13,18]. 
using salmonella to sensitize the immune system 
to the presence of tumors: 
The ignorance of the immune system to the presence 
of tumors within the body is a significant consideration 
in attempting to treat cancer. While numerous methods 
have been attempted to alert the immune system to the 
presence of tumors, recent work has shed new light on the 
role that Salmonella, in particular, plays in this process. 
S. Typhimurium infection of cancer cells was shown to 
upregulate the cellular protein connexin43, resulting in 
gap junction formation not only between tumor cells but 
also between cancer cells and antigen presenting cells 
(APCs) [34]. This allows APCs access to pre-processed 
tumor antigens, which they can then present to T-cells, Oncotarget 2010; 1:  721 - 728 725 www.impactjournals.com/oncotarget
sensitizing the immune system to the presence of tumors 
and activating an anti-tumor response. This ability to 
sensitize the immune system to the presence of tumors 
may explain some of the success Salmonella has in 
combating tumors. Alternative methods of sensitizing the 
immune system through Salmonella targeting of tumors 
have also been used. 
Other approaches employ S. Typhimurium to deliver 
cytokines to the tumor site in an attempt to activate 
immune cells or elicit an immune response against the 
tumor [8,10,35,36,37,38,39]. Antigens have also been 
linked to bacterial toxins that are highly immunogenic to 
sensitize the immune system against cancer cell antigens 
[10,40]. Again, this approach harnesses the ability of S. 
Typhimurium to deliver immune sensitizing compounds 
at the tumor site to alert circulating immune cells, while 
at the same time the bacteria target the more difficult to 
reach anoxic regions of the tumor. 
using bacterial toxins to directly activate 
caspase-3: 
It is becoming increasingly evident that the ability 
to control or inhibit apoptosis affords a distinct advantage 
to certain bacterial pathogens, as it allows the organism 
to replicate within the infected cell, increasing the chance 
of a successful infection. Although a number of bacteria 
specifically inhibit apoptosis, our recent evidence indicates 
that  S.  Typhimurium  may  activate  specific  apoptotic 
enzymes [41]. We found that activation of caspase-3 by 
a single effector protein of S.  Typhimurium increases 
the infectivity of this pathogen, as caspase-3 directed 
the processing of S. Typhimurium secreted effectors into 
their functional subunits upon their delivery into the host 
cell [42]. Such an unprecedented means of promoting 
infection indicates that the interaction of bacteria with 
apoptotic pathways may be more intimate than previously 
recognized, and in fact, may be quite common amongst 
pathogens. 
This observation raises a key question with regards 
to  S. Typhimurium therapy for cancer - can we use 
bacteria to exploit apoptotic pathways, and in particular 
activation of caspase-3, opening a new front in the fight 
against cancer? Direct activation of caspase-3 in the 
treatment of cancer through using procaspase-3 activating 
compounds has been attempted previously using pan 
activating caspase-1 (PAC-1) [43]. Thus, employing 
an efficient bacterial vector to directly deliver a native 
bacterial effector for caspase-3 activation offers a different 
approach to bacterial therapy. Rather than deliver large 
quantities of non native proteins, it may be possible to 
channel the built-in toxicity of S. Typhimurium to destroy 
tumors. S. Typhimurium also harbors several promoters 
that are induced under hypoxic conditions, and using these 
promoters to control expression of specific effectors may 
offer novel opportunities to utilize the innate bacterial 
toxicity. In particular, S. Typhimurium may perhaps be 
engineered to up-regulate caspase-3 through effector 
expression while at the same time introducing potent anti-
cancer drugs that can no longer be successfully expelled 
by the tumor. 
future dIrectIons for 
sAlmonellA cAncer therApy
In sum, bacterial cancer therapy has made great strides 
in past decade, and is now considered a tangible option for 
future cancer therapy. The potential for bacterial therapy 
seems endless but some fundamental issues need to be 
reconciled before this kind of therapy moves into a clinic 
setting. Insufficient colonization of tumors appears to be 
the major obstacle identified in clinical trials, a problem 
that was not evident in animal models. Overcoming 
this challenge is one of the priorities in developing 
bacteria as cancer therapy agents. But the ease of genetic 
manipulation in S. Typhimurium may prove to be the key 
in surmounting this hurdle. Toxicity of S. Typhimurium 
is also problematic, with the bacteria too attenuated to 
destroy tumors once at the tumor site due to toxin removal, 
or poor expression of anti-cancer compounds, or the risks 
of toxicity are too great for injection of S. Typhimurium 
into severely immunocompromised patients. Overcoming 
these limitations, particularly with respect to using 
bacterial proteins in therapy, are key to moving this aspect 
of bacterial cancer therapy forward. 
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